Reports Q1 revenue $52.6M, consensus $53.86M. “The Company is off to a solid start to the year, with record first quarter MACI revenue and total Company revenue, and continued strength in the key performance indicators for the MACI Arthro launch,” said Nick Colangelo, President and CEO of Vericel (VCEL). “Based on the positive trends across the business to start the second quarter, we expect strong revenue growth and profitability in the second quarter and for the remainder of the year as the Company is well-positioned for continued high revenue and profit growth in 2025 and beyond.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- VCEL Earnings this Week: How Will it Perform?
- Vericel Shareholders Approve Key Proposals at Annual Meeting
- Vericel’s Strong Market Position and Growth Prospects Drive Buy Rating Amid Economic Resilience
- Vericel price target lowered to $60 from $63 at BTIG
- Vericel Sees Minimal Impact from U.S. Tariffs